FORA Capital’s ALX Oncology ALXO Stock Holding History

FORA Capital’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-333	Closed	-$18K	–	364
2021 Q2	$18K	Buy	+333	New	+$19.9K	﹤0.01%	833

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

FORA Capital's ALXO Position: Q3 2021 in Review

FORA Capital sold out of ALX Oncology (ALXO) in Q3 2021, closing a stake of 333 shares — an estimated $18K sold.

FORA Capital first reported a position in ALXO in Q2 2021 and held it in 1 quarter. The position peaked at $18K in Q2 2021. 114 funds tracked by Wall St. Rank hold ALXO as of Q3 2021.

FORA Capital reported no remaining ALX Oncology position as of Q3 2021 after selling out during the quarter.
FORA Capital sold 333 ALX Oncology shares in Q3 2021, an estimated $18K.
FORA Capital first reported a position in ALX Oncology in Q2 2021 and held it in 1 quarter.
FORA Capital's ALX Oncology position peaked at $18K in Q2 2021.
114 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2021.

Based on FORA Capital's 13F filing for Q3 2021, filed 15 Nov 2021.